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as well as daily functional status associated with 
PAD and treatment process.2 For this reason, 
objective clinical assessments were extended by 
patient ‑reported outcome measures. The most 
common generic questionnaires, the Medical 
Outcome Study Short Form ‑36 (SF ‑36)3 and 
INTRODUCTION Chronic limb ischemia has an ad‑
verse effect on the quality of life.1 Evaluation of 
the outcomes of peripheral arterial disease (PAD) 
treatment based on objective clinical parame‑
ters does not allow for a reliable assessment of 
pain discomfort, social and emotional aspects, 
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ABSTRACT
INTRODUCTION Objective clinical assessments should include patient ‑reported outcome measures. 
VascuQol is an established disease ‑specific questionnaire assessing the quality of life in patients with 
peripheral artery disease (PAD). Quality ‑of ‑life questionnaires require geographical localization and validation.
OBJECTIVES The goal of this study was to validate the Polish version of the VascuQol: a patient ‑reported 
health ‑related quality ‑of ‑life (HRQoL) instrument specific for PAD.
PATIENTS AND METHODS The linguistic validation of VascuQol followed Mapi Institute methodology. 
Clinical validation process compared VascuQol, EQ ‑5D ‑3L, and SF ‑36 questionnaires in 100 patients 
with both intermittent claudication and critical limb ‑threatening ischemia. Cronbach α coefficients for 
reliability, receiver operating characteristic curves for clinical discriminative performance, standardized 
response means for responsiveness, and Pearson correlations for construct validity were evaluated. 
Additionally, in a separate cohort of 58 patients with stable disease, the test–retest was characterized 
with intraclass correlation, Bland–Altman analysis, and Pearson correlation coefficients.
RESULTS VascuQol proved to perform better than SF ‑36 and EQ ‑5D ‑3L. Cronbach α coefficients showed 
good internal consistency (α values >0.9 for all summary scores). All test–retest Pearson r values for 
VascuQol were above 0.70. The intraclass correlation of absolute agreement consistency exceeded 0.8. 
The Bland–Altman 95% limits of agreement were between 2.72 and 4.87. There were strong and moderate 
correlations for total scores in all domains between VascuQol and SF ‑36, and for most of the domains 
between VascuQol and EQ ‑5D ‑3L.
CONCLUSIONS The Polish version of VascuQol is a sensitive, accurate, and reliable tool for assessing 
HRQoL in patients with PAD.
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The respective domains can be combined into 
2 summary measures, representing physical com‑
ponent summary score (PCS) and mental com‑
ponent summary score (MCS). The SF ‑36v2 is 
available as a validated Polish version,21 which 
was kindly provided by Medical Outcomes Trust 
and Quality Metric Incorporated22 (Hanover, 
New Hampshire, United States).  
The EQ ‑5D ‑3L questionnaire The EQ ‑5D ‑3L ques‑
tionnaire is a generic quality of life instrument. It 
consists of 2 parts. The descriptive part includes 
5 questions regarding mobility, self ‑care, usual 
activities, pain, and anxiety/depression. They are 
further graded into levels of severity correspond‑
ing to “no problems” (level 1), “some problems” 
(level 2) and “extreme problems” (level 3). EQ‑
‑5D ‑3L health states, defined by the EQ ‑5D ‑3L 
descriptive system, may be converted to a single 
index value ranging from 0.59 (values for qual‑
ity of life worse than death) to 1 (good quality 
of life status) (EQ Index). The second part in‑
cludes a visual analog scale (EQ ‑VAS), on which 
patients can assess their health on a scale from 
0 to 100. EQ ‑5D ‑3L has a validated Polish ver‑
sion,23 which was kindly provided by the Euro‑
Qol Research Foundation (Rotterdam, the Neth‑
erlands). The Polish value set and index calcula‑
tor were kindly provided by Dominik Golicki, 
MD, PhD (Warsaw Medical University, Warsaw, 
Poland).
In this paper, we refer to questionnaires or 
tools when speaking about HRQoL evaluation 
instruments, and to tests when speaking about 
specific statistical assays.
PATIENTS AND METHODS Linguistic valida‑
tion The Polish version of the VascuQol was 
developed using a standard linguistic valida‑
tion process developed by Mapi.20 The concep‑
tual analysis of the original VascuQol was per‑
formed with Mark Morgan, the developer of 
the initial questionnaire. As a result, a sum‑
mary file explaining the meaning of each item 
and denoting terms for each concept was pro‑
vided to the translation team. This analysis al‑
lowed consistency of the Polish version with 
the original. Dual forward translation and sin‑
gle back translation followed by the reviews of 
a local team leader and Dr. Morgan allowed to 
develop the Polish linguistic translation text. 
Then, the resulting translation was examined 
on 5 patients with lower limb ischemia (face‑
‑to ‑face interviews). Attention was paid to as‑
sure equal representation of gender and mixed 
education (ie, a minimum of 2 participants with 
less than 15 years of school attendance). Pa‑
tients were asked to complete the Polish ver‑
sion of the VascuQol and raise any issues with 
understanding the instructions, items them‑
selves, or response scales. They were asked to 
paraphrase each sentence in the questionnaire 
or reformulate it in their own words. The inter‑
viewer evaluated the patients’ understanding of 
the EuroQoL ‑5D (EQ ‑5D‑3L)1 are not sufficiently 
sensitive to accurately measure deterioration in 
the quality of life related to limb ischemia, func‑
tional walking impairment, and treatment pro‑
cess. Therefore, specific questionnaires were re‑
quired and developed. They include, but are not 
limited to, the Walking Impairment Question‑
naire,4 Claudication Scale questionnaire,5 Pe‑
ripheral Artery Questionnaire,6 PAD Quality of 
Life Questionnaire,7 and Intermittent Claudica‑
tion Questionnaire (ICQ).8 Some of these instru‑
ments were validated for local languages other 
than English.9‑12
Although the quality of life in patients with 
PAD was systematically evaluated in Poland,13,14 
mostly general questionnaires were used. Only 
recently, the Intermittent Claudication Ques‑
tionnaire, a PAD ‑specific health ‑related quality 
of life (HRQoL) questionnaire was validated in Pol‑
ish.15 We selected another questionnaire specific 
to HRQoL in PAD, namely, the Vascular Quality 
of Life Questionnaire (VascuQol), because it cov‑
ers not only a spectrum of claudication symptoms 
but also demonstrates good reliability in evaluat‑
ing patients with CLTI, who frequently present 
at our center.16
Characteristics of the VascuQol The VascuQol 
consists of 25 questions covering 5 domains: 
activities, symptoms, pain (physical domains), 
as well as emotions and social behavior (men‑
tal domains). The answer to each question is 
rated with a 7 ‑point scale, where 1 stands for 
the worst, and 7, for the best rating. The ques‑
tionnaire was developed by Mark Morgan, MD, 
from the Surgical Unit of King’s College Hospi‑
tal in London.17 The VascuQol questionnaire was 
used in the BASIL study (Bypass vs Angioplasty 
in Severe Ischaemia of the Leg)18 and has after‑
ward been translated and validated in other Eu‑
ropean countries where high psychometric val‑
ue and applicability in PAD patients was con‑
firmed.9,11,19 The linguistic validation of the Vas‑
cuQol in several languages was carried out using 
Mapi’s methodology.20 Within 25 years, Mapi 
has linguistically validated more than 2500 in‑
struments in over 170 languages in a wide range 
of therapeutic areas. Due to cultural differences 
between nations, the validation process should 
include both linguistic and cultural adaptation 
and clinical efficacy of the questionnaire.
Characteristics of the generic quality ‑of ‑life instru‑
ments The SF ‑36 questionnaire The SF ‑36 is 
the world’s most widely used generic question‑
naire to assess the quality of life in patients with 
cardiovascular diseases (including PAD). The in‑
strument consists of 36 items, which evaluate 
8 health domains, namely, physical functioning, 
role physical, bodily pain, general health, vitali‑
ty, social functioning, role emotional, and men‑
tal health. Each item is encoded and converted to 
contribute to subscale scores from 0 (worst pos‑
sible results) to 100 points (best health status). 
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Statistical methods and calculations Descriptive 
statistics was used. Statistical significance for 
nominal data was assessed by the χ2 test, and 
the Mann–Whitney test was used for numeri‑
cal data.
For VascuQol internal reliability assessment, 
Cronbach α coefficients were calculated for each 
domain and for the total score.
The receiver operating characteristic (ROC) 
curves and areas under the curve (AUC) were 
evaluated and compared to determine the abil‑
ity of the VascuQol and other tools to discrim‑
inate between patients with intermittent clau‑
dication (IC) and critical limb ‑threatening isch‑
emia (CLTI) before treatment. DeLong nonpara‑
metric method24 was applied to compare differ‑
ences between ROC curves.
For the test–retest cohort, intraclass correla‑
tions (ICC) and Bland–Altman limits of agree‑
ment (LOA) were calculated.
Responsiveness was assessed by evaluating 
significance of differences between the values 
for each domain before and after treatment 
(Wilcoxon signed ‑rank test). Also, standardized 
response means (SRMs) were calculated accord‑
ing to Husted et al25 for each domain of the Vas‑
cuQol, SF ‑36, EQ Index, and EQ ‑VAS, as well 
as for the ankle–brachial pressure index (ABPI) 
and clinical presentation according to the Ruth‑
erford clinical scale.26 The SRMs were calculat‑
ed as the mean difference in score 1 month af‑
ter endovascular treatment as compared with 
baseline, divided by the standard deviation of 
the difference.
Cohen criteria for interpreting effect sizes 
were applied (small effect size ≥0.2 and <0.5; 
moderate effect size ≥0.5 and <0.8; large effect 
size ≥0.8). The construct validity of the Vas‑
cuQol was tested by a correlation analysis ver‑
sus the SF ‑36 subscales, EQ Index, EQ ‑VAS, 
and ABPI, using the Pearson correlation coeffi‑
cient. Statistical analysis was performed using 
SPSS version 18.0 (SPSS Inc. Chicago, Illinois, 
United States).
Study population Linguistic validation We recruit‑
ed 5 patients with lower limb ischemia (2 wom‑
en and 3 men), all native ‑speaking residents of 
Poland. They ranged in age from 63 to 78 years 
old (mean, 70.8 years). All had at least 8 years 
of education.
Clinical validation Between October 2016 and 
November 2016, we enrolled 100 consecutive 
patients with PAD for clinical validation purpos‑
es. Fifty patients presented with IC (Rutherford 
class 3) and 50 with CLTI (Rutherford class 4, n 
= 19; class 5, n = 18; and class 6, n = 13). Except 
for the disease stage, there were no significant 
differences in demographic and clinical charac‑
teristics of the patients between the CLTI and IC 
groups. The characteristics of the study cohort 
are presented in TABLE 1.
the concept behind each item (“Were they able 
to provide the meaning of each item?”) and rea‑
sons for any difficulties in this respect (ie, inac‑
curate translation or missing cultural relevance 
for the concept). Similarily, the interviewer ver‑
ified the cultural relevance of the translation. 
Alternative wording was provided as needed. 
Difficulties and suggestions for all instructions, 
items, and response categories were summa‑
rized in a tabelarized synopsis and analyzed be‑
fore the final version was produced.
The issues encountered during the process and 
decisions made to solve them were documented 
and categorized (as cultural, idiomatic, pragmat‑
ic, semantic, and syntactic).
Clinical validation Clinical validation of the Pol‑
ish version of VascuQol was conducted prospec‑
tively in consecutive patients referred for endo‑
vascular treatment due to PAD in a single large‑
‑volume tertiary angiology center in southern 
Poland. Patient exclusions were exceptional, not 
predefined, and concerned only patients refusing 
participation, not able to attend follow ‑up visits, 
or not able to read and fill in the questionnaire 
in Polish. Patients were evaluated simultane‑
ously using 3 HRQoL tools: validated Polish ver‑
sions of the EQ ‑5D ‑3L and SF ‑36v2 and the ana‑
lyzed version of the VascuQol. The questionnaires 
were administered shortly before treatment and 
1 month after revascularization.
An additional sample of patients treated in 
our center was recruited to determine the test–
retest stability of the VascuQol. Patients were 
in a stable phase of the disease and were tested 
twice within 4 weeks. Disease stage distribution 
was similar to the first cohort.
TABLE 1 Characteristics of the clinical validation cohort: demographic data, risk 
factors, comorbidities
Parameter All patients 
(n = 100)
CLTI  
(n = 50)
IC  
(n = 50)
P valuea
Median age, range 68 (49–99) 69 (55–99) 67 (49–81) 0.051
Male sex, % 83 78 88 0.18
Smoking, % 78 72 82 0.33
Diabetes, % 36 44 30 0.21
Hypertension, % 65 66 64 0.83
Lipid disorders, % 40 44 36 0.41
CHD, previous MI, % 39 42 36 0.54
Kidney diseaseb, % 12 14 10 0.54
COPD, % 12 8 16 0.22
TIA/stroke, % 4 6 2 0.31
a Significance for nominal data was assessed by the χ2 test, and for the numerical 
data, by the Mann–Whitney test.
b GFR <60 ml/min/1.73 m2
Abbreviations: CHD, coronary heart disease; CLTI, critical limb ‑threatening ischemia; 
COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; IC, 
intermittent claudication; MI, myocardial infarction; TIA, transient ischemic attack
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equivalent of “missing sensation.” The new ver‑
sion was retested on patients who, this time, un‑
derstood the intended meaning. The addition of 
“missing sensation” made the Polish item broad‑
er in meaning as it included feelings such as “par‑
alyzed, foreign body, not sensitive to touch, as if 
not mine.”
Item 11 (“In the last two weeks being [or be‑
coming] housebound has been a  concern of 
mine…”) was problematic because of 2 challeng‑
es: 1) the use of the idiomatic expression “house‑
bound” which requires translation with a periph‑
rasis, i.e., “unable to leave home”; and 2) the jux‑
taposition of an existing situation (being) with 
a hypothetical one (becoming), which raised much 
discussion about the syntax of the Polish version 
and on how to make it clear and not complicated 
to respondents. Several translations were tested, 
and the following option was chosen: “In the last 
two weeks I worried about that now, or in the fu‑
ture, I may be unable to leave home.”
As for item 15 (“In the last two weeks because 
of the poor circulation to my legs, my ability to 
take part in social activities has been…”), the is‑
sue concerned the phrase “to take part in social 
activities.” It required translation into an equiva‑
lent of “to participate in social and public life” for 
a better understanding by the patients.
The main issue in item 19 (“In the last two 
weeks problems caused by poor circulation to 
the legs have made me feel frustrated…”) was 
the use of “frustrated” in the original. The trans‑
lation team felt that the patients would not eas‑
ily understand a literal translation. It was decid‑
ed to use the substantive, “frustration”, instead, 
and to add the term “discouragement” to convey 
the meaning of a deep chronic sense or a state of 
insecurity and dissatisfaction arising from being 
unable to change or achieve something.
Finally, item 5 (“In the last two weeks my legs 
have felt tired or weak…”) was not an issue, but in‑
terestingly, all respondents used the term “heavy” 
to describe their feeling.
Reliability The  values of Cronbach α coeffi‑
cients for the VascuQol summary score were in 
the range of 0.92 to 0.98 and exceeded 0.7 for 
most of the VascuQol domains.
For the  “symptoms” subscale in the  pre‑
test for CLTI and IC groups, the α values were 
0.6 and 0.58, respectively. The α coefficients for 
the “symptoms” domain in the posttest for CLTI 
and IC groups were 0.84 and 0.87, respective‑
ly. The results for all subscales are presented in 
TABLE 3.
Diagnostic reference Baseline VascuQol scores 
were significantly lower in the CLTI group, both 
for all and for each separate domain (TABLE 4). Simi‑
larly, the differences were significant in the gener‑
ic SF ‑36 and EQ ‑5D ‑3L questionnaires (Supple‑
mentary material, Table S1). The ROC curves and 
AUCs confirmed a high ability of the VascuQol 
to discriminate the clinical status of patients 
We also enrolled a group of 58 patients to as‑
sess the test–retest stability. Their characteristics 
are presented in TABLE 2.
RESULTS Linguistic validity No cultural issues 
were encountered during the translation process. 
For all items, the most prevalent problem was syn‑
tactic with the use of the preterit equivalent tense 
in Polish to render the use of the present per‑
fect tense in the original English questionnaire. 
Of the 25 items, 6 generated difficulties, most‑
ly semantic and syntactic (ie, items 3, 8, 11, 15, 
19, and 20). The addition of the adjective “physi‑
cal” in the response categories of items 3, 8, and 
20 (“very great deal of discomfort or distress” to 
“no discomfort or distress”) clarified the mean‑
ing of the original and enabled a better under‑
standing by the patients.
The translation of item 8 (“In the last two weeks 
pins and needles or numbness in my leg [or foot] 
have caused me …”) was challenging. The Pol‑
ish version tested on patients (back ‑translation: 
“In the last two weeks tingling or going numb of 
the leg [or foot] caused me…”) was not entirely 
understood as it should have been. Patients kept 
referring to “stiffness” and not to “numbness,” 
that is, lack of sensation. Therefore, it was decid‑
ed to change the translation and add the Polish 
TABLE 2 Characteristics of the test–retest cohort (n = 58): demographic data, risk 
factors, comorbidities
Rutherford class, median (range) 4 (3–6)
Age, median (range) 70 (38–97)
Male sex, % 71
Smoking, % 50
Diabetes, % 48
Hypertension, % 79
Lipid disorders, % 41
CHD, previous MI, % 52
Kidney diseasea, % 19
COPD, % 5
TIA/stroke, % 9
a GFR <60 ml/min/1.73 m2
Abbreviations: see TABLE 1
TABLE 3 Cronbach α values for the VascuQol domains in patients with critical limb‑
‑threatening ischemia and intermittent claudication
Domain CLTI IC
Pretest  
(n = 50)
Posttest  
(n = 50)
Pretest  
(n = 50)
Posttest  
(n = 50)
Activities 0.72 0.93 0.88 0.94
Symptoms 0.60 0.84 0.53 0.87
Pain 0.78 0.90 0.80 0.92
Emotions 0.85 0.95 0.89 0.93
Social 0.78 0.82 0.80 0.84
Total score 0.92 0.98 0.95 0.98
Abbreviations: see TABLE 1
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Responsiveness Specific changes in the evalu‑
ated questionnaires found after treatment are 
shown in TABLE 8. Additional data are presented 
in Supplementary material, Figures S8 and S9). 
While the results obtained before and after treat‑
ment have changed, the difference reached sig‑
nificance for all domains only in the VascuQol. 
The SRMs for the VascuQol in both groups were 
in the range of 0.61 to 1.1. The SRMs for the total 
VascuQol score both in CLTI and IC groups were 
higher than 0.8. Conversely, SRMs for EQ ‑5D ‑3L 
and EQ ‑VAS were lower than 0.5 in both groups. 
The SF ‑36 demonstrated good responsiveness 
(good for PCS and medium for MCS).
Construct validity The total score of the VascuQol 
in both groups (CLTI and IC) correlated strong‑
ly and moderately with the physical and mental 
component summary scores in the SF ‑36 and 
EQ Index (r values in the range of 0.51 to 0.76; 
P <0.001). Strong or moderate correlations were 
also observed between the VascuQol and SF‑
‑36 for pain subscales (r values in the range of 
0.45 to 0.63; P <0.01). Strong correlations were 
also obtained between physical and mental do‑
mains of VascuQol and PCS and MCS components 
of SF ‑36, respectively. ABPI correlated poorly with 
any of the VascuQol domains and generic ques‑
tionnaires. Details are shown in Supplementary 
material, Tables S3–S6.
DISCUSSION Evaluation of the effects of treat‑
ment based on patient ‑reported outcome mea‑
sures is an important part of good clinical prac‑
tice. Although recent efforts of Rosloniec et al15 
have resulted in the first disease‑specific HRQoL 
instrument for PAD that is validated in Polish, it 
would be not adequate for patients with CLTI, 
as they can barely walk.16 Literature reports and 
a review of available HRQoLs questionnaires in‑
dicated that the VascuQol is a robust tool for 
the assessment of the quality of life in PAD with 
a wide spectrum of clinical stages of the dis‑
ease.16,17 Therefore, we decided to perform a lin‑
guistic and clinical validation of the VascuQol in 
Polish. The methodology developed by Mapi20 
was used to carry out a linguistic validation of 
the VascuQol, and a clinical evaluation was done 
using a previously described methodology for 
other languages.9,11,27
Our analysis showed that the Polish version of 
VascuQol is adequate to evaluate patient ‑reported 
outcomes in PAD in patients undergoing endo‑
vascular treatment. The results of the linguistic 
validation demonstrated that the Polish version 
of the questionnaire is conceptually equivalent to 
the original. The Bland–Altman analysis28 showed 
repeatability of the questionnaire, demonstrating 
a good agreement between test and retest results 
in stable patients with both CLTI and IC. Even 
though the VascuQol consists of 7 grades that 
define the whole spectrum of the quality of life, 
and therefore repeatability is difficult to prove, 
we found a concordance of test–retest results. 
between IC and CLTI. A comparison of the AUC 
between the questionnaires has shown the high‑
est value for the VascuQol, equal to 0.8. Details 
are shown in TABLE 5 and in Supplementary ma‑
terial, Figure S1.
Test–retest reliability All the test–retest Pearson 
correlation coefficients for the VascuQol were 
above 0.70 (Supplementary material, Table S2). 
The ICC of the absolute agreement consisten‑
cy between the pretest and posttest, based on 
a 2 ‑way mixed model for all measures, was above 
0.8 (TABLE 6). For the entire range of possible an‑
swers to the VascuQol questions, the Bland–Alt‑
man 95% limits of agreement values were be‑
tween 2.72 to 4.87. Numerical data are shown in 
TABLE 7, and the Bland–Altman graphs are avail‑
able in Supplementary material, Figures S2–S7).
TABLE 4 Mean VascuQol scores before treatment in patients with critical limb‑
‑threatening ischemia and intermittent claudication
Domain CLTI (n = 50) IC (n = 50) P valuea
Activities 2.20 (0.80) 3.00 (1.26) <0.001
Symptoms 2.50 (1.07) 4.00 (1.08) <0.001
Pain 2.30 (0.90) 3.20 (1.30) <0.001
Emotions 2.60 (1.08) 4.10 (1.49) <0.001
Social 2.70 (1.58) 3.70 (1.70) 0.003
Total score 2.40 (0.75) 3.55 (1.18) <0.001
Data are presented as mean (SD).
a Mann –Whitney test
Abbreviations: see TABLE 1
TABLE 5 Area under the curve values for VascuQol, SF ‑36, EQ Index, and ankle– 
–brachial pressure index
AUC SE P value
VascuQol (total score) 0.802 0.044 <0.001
EQ Index 0.738 0.050 <0.001
EQ ‑VAS 0.670 0.055 0.004
PCS 0.709 0.054 <0.001
MCS 0.638 0.056 0.02
ABPI 0.600 0.061 0.08
Abbreviations: ABPI, ankle–brachial pressure index; AUC, area under the curve; MCS, 
mental component summary of SF ‑36; PCS, physical component summary of SF ‑36; 
SE, standard error
TABLE 6 VascuQol intraclass correlation results
Domain ICC 95% CI P value
LL UL
Activities 0.88 0.80 0.93 <0.001
Symptoms 0.89 0.82 0.94 <0.001
Pain 0.83 0.71 0.90 <0.001
Emotions 0.92 0.86 0.95 <0.001
Social 0.80 0.67 0.88 <0.001
Total score 0.90 0.84 0.94 <0.001
Abbreviations: ICC, intraclass correlations coefficient; LL, lower limit; UL, upper limit
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homogeneity, and factor analysis. Some items 
were found to perform weak in a clinimetric anal‑
ysis. Additionally, a 3 ‑factor solution was sug‑
gested to reduce score variance. As we also not‑
ed that some items performed worse, we planned 
a similar evaluation for the next cohort of our pa‑
tients, for the Polish version, and after the vali‑
dation study.
Nevertheless, we believe that valuation of clin‑
ical questionnaires should rely on content validity 
and clinical usefulness rather than on internal con‑
sistency.11,30 The VascuQol demonstrated satisfac‑
tory responsiveness in a number of studies,17,31 in 
various populations and language versions.
The reliability of the Polish VascuQol was found 
to be acceptable by all measures, with the values of 
ICC above 0.8, according to the criteria defined by 
Terwee et al.32 While Heerkens et al33 recommend‑
ed values over 0.9 for the monitoring of ongoing 
Internal consistency for this instrument was ex‑
cellent for the summary score and acceptable for 
almost all domains. The only domain that showed 
a relatively low α value for the scale items was 
the “symptoms” domain in pretest (<0.7), but 
in a posttest assessment, it exceeded the value 
of 0.8. Nordanstig et al11 who conducted valida‑
tion in the Swedish population noted a similar low 
value for the “symptoms” domain. Traditionally, 
psychometry scaling assumes all items to be “ef‑
fect indicators” manifesting the same latent con‑
struct with a high correlation structure and inter‑
nal consistency.11 Conversely, “causal indicators” 
(eg, symptoms) are subjective. Therefore, they re‑
veal a weaker correlation structure and lower in‑
ternal consistency in many cases.
A recent evaluation of the Dutch version of 
the VascuQol by Conijn et al29 provided addi‑
tional information on the questionnaire validity, 
TABLE 8 Health‑related quality of life instruments in domain scores in the study population before and after treatment
Domain CLTI IC
Pretest Posttest ∆ P valuea SRM Pretest Posttest ∆ P valuea SRM
VascuQol Activities 2.2 (0.8) 3.3 (1.6) 1.1 (1.3) <0.001 0.86 3.0 (1.2) 4.5 (1.5) 1.5 (1.6) <0.001 0.94
Symptoms 2.5 (1.1) 3.9 (1.4) 1.3 (1.5) <0.001 0.90 4.0 (1.0) 4.8 (1.4) 0.8 (1.1) <0.001 0.7
Pain 2.3 (0.9) 3.7 (1.3) 1.4 (1.3) <0.001 1.1 3.2 (1.3) 4.6 (1.6) 1.4 (1.3) <0.001 1.0
Emotions 2.6 (1.1) 3.8 (1.6) 1.2 (1.3) <0.001 0.9 4.1 (1.50) 4.8 (1.6) 0.7 (1.0) <0.001 0.69
Social 2.7 (1.6) 3.8 (1.8) 1.1 (1.5) <0.001 0.76 3.7 (1.7) 4.7 (1.8) 1.1 (1.8) <0.001 0.61
Total score 2.4 (0.7) 3.6 (1.4) 1.2 (1.2) <0.001 1.0 3.5 (1.2) 4.6 (1.5) 1.1 (1.2) <0.001 0.93
EQ ‑5D‑ 
‑3L
EQ index 0.5 (0.2) 0.6 (0.2) 0.1 (0.2) 0.001 0.51 0.64 (0.2) 0.69 (0.2) 0.05 (0.2) 0.104 0.24
EQ ‑VAS 44.4 (17.0) 53.1 (17.4) 8.7 (15.5) 0.001 0.49 51.9 (11.6) 60.8 (18.1) 8.9 (16.6) 0.001 0.53
SF ‑36 PCS 25.3 (13.6) 38.5 (17.7) 13.2 (14.8) <0.001 0.89 33.4 (11.3) 45.0 (10.6) 11.6 (8.7) <0.001 1.3
MCS 36.6 (17.7) 46.3 (17.5) 9.7 (12.1) <0.001 0.79 45.3 (17.0) 54.4 (12.5) 9.0 (12.6) <0.001 0.71
BP 19.6 (16.9) 23.6 (24.0) 24.0 (21.8) <0.001 1.1 28.8(12.1) 46.4(10.9) 17.6 (10.9) <0.001 1.6
SF 33.0 (26.2) 44.8 (23.4) 11.8 (22.0) 0.001 0.53 45.8 (20.1) 54.8 (16.4) 9.0 (18.9) 0.003 0.47
PF 20.6 (20.0) 34.7 (23.5) 14.1 (18.3) <0.001 0.76 30.6 (16.4) 40.6 (12.7) 10.0 (13.2) <0.001 0.75
RP 22.9 (20.4) 38.2 (24.3) 15.4 (17.7) <0.001 0.86 31.0 (18.7) 46.0 (15.7) 15.0 (15.5) <0.001 0.96
MH 43.4 (16.2) 54.7 (12.8) 11.3 (13.0) <0.001 0.86 48.1 (17.2) 59.7 (11.2) 11.6 (14.8) <0.001 0.78
GH 38.2 (12.6) 37.4 (11.5)  – 0.8 (11.5) 0.55  – 0.06 43.4 (11.5) 47.1 (12.2) 3.7 (10.2) 0.028 0.36
VT 34.0 (17.5) 42.9 (14.9) 8.9 (13.1) <0.001 0.67 37.5 (16.4) 50.0 (11.3) 12.5 (11.8) <0.001 1.12
RE 36.0 (26.4) 42.8 (26.5) 6.8 (17.8) 0.002 0.38 50.0 (27.8) 53.0 (21.8) 3.0 (21.0) 0.24 0.14
Data are presented as mean (SD). ∆ denotes difference between post‑ and pretest.
a Wilcoxon signed ‑rank test
Abbreviations: BP, bodily pain; GH, general health; MH, mental health; PF, physical functioning; RE, role emotional; RP, role physical; SD, standard 
deviation; SF, social functioning; SRM, standardized response mean; VT, vitality; others, see TABLES 1 and 5
TABLE 7 VascuQol Bland–Altman analysis
Domain Mean difference SD of difference SE of difference 95% CI for mean difference Limit values for 95% LOA
Activities  – 0.05 0.71 0.09  – 0.24 0.13  – 1.45 to 1.33
Symptoms 0.14 0.81 0.11  – 0.07 0.35  – 1.46 to 1.73
Pain  – 0.02 0.99 0.13  – 0.28 0.24  – 1.94 to 1.91
Emotions 0.08 0.76 0.10  – 0.12 0.28  – 1.41 to 1.57
Social  – 0.03 0.23 0.16  – 0.36 0.29  – 2.45 to 2.38
Total score 0.02 0.69 0.09  – 0.16 0.21  – 1.33 to 1.38
Abbreviations: LOA, Bland–Altman limits of agreement
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ity of life of Polish patients with symptomatic 
PAD.
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